{"id":"NCT01004263","sponsor":"Organon and Co","briefTitle":"A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)","officialTitle":"A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12-01","primaryCompletion":"2011-04-18","completion":"2011-04-18","firstPosted":"2009-10-29","resultsPosted":"2012-05-04","lastUpdate":"2024-04-22"},"enrollment":674,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Migraine With or Without Aura in Adolescents"],"interventions":[{"type":"DRUG","name":"rizatriptan benzoate","otherNames":["MK-0462","Maxalt"]}],"arms":[{"label":"Rizatriptan","type":"EXPERIMENTAL"}],"summary":"To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17 years.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose","timeFrame":"Up to 24 hours post dose","effectByArm":[{"arm":"Rizatriptan","deltaMin":322,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23078588"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":606},"commonTop":["Accidental overdose","Dizziness","Nasopharyngitis","Somnolence","Nausea"]}}